A study evaluated the feasibility of EUS-guided fine-needle biopsy (EUS-FNB) for next-generation sequencing (NGS) in unresectable pancreatic ductal adenocarcinoma (PDAC). The technical yield of EUS-FNB met criteria in 48% of cases, while the molecular yield was remarkably high at 98%. This means that nearly all qualifying biopsies provided sufficient DNA for mutation detection. Most frequently mutated genes were identified, contributing important insights for targeted treatment possibilities in this lethal cancer.
Journal Article by Buchberg J, de Stricker K (…) Detlefsen S et 2 al. in Endosc Ultrasound
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc on behalf of Scholar Media Publishing.